Boston Scientific commences another stent trial

May 26, 2010 by MassDevice staff

Boston Scientific Corp. begins a trial to compare its Promus Element stent with Abbott's Xience Prime.

BSX logo

Boston Scientific Corp. (NYSE:BSX) set out to compare its new Promus Element drug-eluting stent system with Abbott's (ABT) Xience Prime.

The BSX-funded study will evaluate coronary revascularization outcomes in a 2,980-patient sample across 50 sites in France, Germany, Italy, Spain and the U.K.

Former iterations of the Promus line were private-label versions of Abbott’s Xience V drug-eluting stents, but the Natick, Mass.-based stent pioneer's deal to rebrand its rival's devices ended last year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp